What do systematic reviews say?

Fluorescence imaging / light-based techniques vs No screening

The review found no eligible studies for this question.

• Screening programmes for the early detection and prevention of oral cancer 2013 · Cochrane All outcomes
  There was no evidence to support the use of adjunctive technologies like toluidine blue, brush biopsy or fluorescence imaging as a screening tool to reduce oral cancer mortality; no eligible randomised controlled trial…
  0 studies
  No studies found

Antifungal drugs partially absorbed from GI tract (miconazole, clotrimazole) vs placebo or no treatment

Antifungal drugs partially absorbed from GI tract (miconazole,… showed no clear difference in systemic fungal infection compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 2.27 [0.23, 22.56]
  1 study · 32 participants
  GRADE not reported

Itraconazole vs Fluconazole

Itraconazole showed no clear difference in empirical antifungal treatment compared with fluconazole; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.5 [0.05, 5.43]
  1 study · 202 participants
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in systemic fungal infection compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.65 [0.37, 1.14]
  6 studies · 1041 participants
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  No trial reported this planned secondary outcome for any comparison in this review
  Studies not reported
  No studies found

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… led to lower empirical antifungal treatment compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.85 [0.73, 0.99]
  2 studies · 465 participants
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in good compliance compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 1.06 [0.89, 1.27]
  2 studies · 615 participants
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  No trial reported this planned secondary outcome for any comparison in this review
  Studies not reported
  No studies found

Antifungal drugs partially absorbed from GI tract (miconazole, clotrimazole) vs placebo or no treatment

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  2 studies, 60 participants; effect not estimable (no events reported)
  2 studies · 60 participants
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in death associated with fungal infection compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 1.44 [0.14, 15.43]
  3 studies · 718 participants
  GRADE not reported

Itraconazole vs Fluconazole

Itraconazole showed no clear difference in systemic fungal infection compared with fluconazole; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 1.0 [0.26, 3.89]
  1 study · 202 participants
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  No trial reported this planned secondary outcome for any comparison in this review
  Studies not reported
  No studies found

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs Antifungal drugs not absorbed from GI tract

Antifungal drugs absorbed from GI tract showed no clear difference in empirical antifungal treatment compared with antifungal drugs not absorbed from GI tract; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.89 [0.68, 1.16]
  4 studies · 1031 participants
  GRADE not reported

Itraconazole vs Fluconazole

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  2 studies, 232 participants; effect not estimable
  2 studies · 232 participants
  GRADE not reported

Norfloxacin plus amphotericin B vs Amphotericin B

Norfloxacin plus amphotericin B showed no clear difference in systemic fungal infection compared with amphotericin B; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.67 [0.2, 2.23]
  1 study · 106 participants
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  No trial reported this planned secondary outcome for any comparison in this review
  Studies not reported
  No studies found

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs Antifungal drugs not absorbed from GI tract

Antifungal drugs absorbed from GI tract showed no clear difference in systemic fungal infection compared with antifungal drugs not absorbed from GI tract; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.59 [0.33, 1.06]
  8 studies · 2103 participants
  GRADE not reported

Itraconazole vs Fluconazole

Itraconazole showed no clear difference in death associated with fungal infection compared with fluconazole; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.14 [0.01, 2.73]
  1 study · 202 participants
  GRADE not reported

Itraconazole vs Fluconazole

Itraconazole showed no clear difference in good compliance compared with fluconazole; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.95 [0.85, 1.05]
  1 study · 202 participants
  GRADE not reported

Antifungal drugs partially absorbed from GI tract (miconazole, clotrimazole) vs placebo or no treatment

Antifungal drugs partially absorbed from GI tract (miconazole,… showed no clear difference in empirical antifungal treatment compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 3.38 [0.15, 77.12]
  1 study · 32 participants
  GRADE not reported